Gene Therapy in Treating Patients With Cancer (NCT00004178) | Clinical Trial Compass
CompletedPhase 1
Gene Therapy in Treating Patients With Cancer
United StatesStarted 1998-04
Plain-language summary
RATIONALE: Inserting a gene that has been created in the laboratory into a person's white blood cells may make the body build an immune response to kill cancer cells.
PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have cancer that has not responded to previous therapy.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DISEASE CHARACTERISTICS:
* Histologically proven CEA expressing adenocarcinoma
* Serum CEA levels greater than 10 ng/mL
* Failed standard therapy
* Measurable disease
PATIENT CHARACTERISTICS:
Age:
* 18 and over
Performance status:
* 0-2
Life expectancy:
* Greater than 2 months
Hematopoietic:
* Not specified
Hepatic:
* No significant hepatic disease
* Bilirubin no greater than 3 mg/dL
* No active clinical disease caused by hepatitis B
Renal:
* No significant renal disease
* Creatinine no greater than 3 mg/dL
Cardiovascular:
* No significant cardiovascular disease
Pulmonary:
* No significant pulmonary disease
Other:
* Not pregnant
* Negative pregnancy test
* Fertile patients must use effective contraception
* No significant endocrine, rheumatologic, or allergic disease
* No active clinical disease caused by cytomegalovirus or tuberculosis
* HIV negative
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* At least 4 weeks since prior chemotherapy
Endocrine therapy:
* Not specified
Radiotherapy:
* At least 4 weeks since prior radiotherapy
Surgery:
* Not specified